Profusa has received a positive decision from GMED regarding ISO 13485 certification for its quality management system, a crucial step towards obtaining a CE Mark for its Lumee Oxygen Platform in the EU. This regulatory progress is a positive development for the company, potentially opening up a significant market for its continuous tissue oxygen monitoring technology.
Profusa, a micro-cap company, announced significant progress in its European regulatory efforts for the Lumee Oxygen Platform. Receiving a positive decision from GMED for ISO 13485 certification is a critical milestone, as it validates the company's quality management system, a prerequisite for the CE Mark. This development is positive for Profusa as it moves closer to commercializing its tissue oxygen monitoring technology in the 27 EU member states, representing a substantial market opportunity. While the company notes that the exact timing and outcome of the CE marking cannot be guaranteed, this news has already led to a significant short-term surge in its stock price. Long-term implications depend on successful CE marking and subsequent market adoption, but this reduces regulatory risk. The acquisition of G3 Vision Labs, mentioned in the filing, indicates a broader strategy to diversify revenue streams, but the immediate catalyst is the regulatory progress.